Early Events in Light Chain Aggregation at Physiological PH Reveal New Insights on Assembly, Stability, and Aggregate Dissociation

Overview

Journal Amyloid

Specialty Biochemistry

Date 2021 Feb 3

PMID 33533277

Citations 5

Authors

Pinaki Misra

Marina Ramirez-Alvarado

Affiliations

Soon will be listed here.

Abstract

Early events in immunoglobulin light chain (AL) amyloid formation are especially important as some early intermediates formed during the aggregation reaction are cytotoxic and play a critical role in the initiation of amyloid assembly. We investigated the early events in aggregation of cardiac amyloidosis AL proteins at pH 7.4. In this study we make distinctions between general aggregation and amyloid formation. Aggregation is defined by the disappearance of monomers and the detection of sedimentable intermediates we call non-fibrillar macromolecular (NFM) intermediates by transmission electron microscopy (TEM). Amyloid formation is defined by the disappearance of monomers, Thioflavin T fluorescence enhancement, and the presence of fibrils by TEM. All proteins aggregated at very similar rates the formation of NFM intermediates. The condensed NFM intermediates were composed of non-native monomers. Amyloid formation and amyloid yield was variable among the different proteins. During the stationary phase, all proteins demonstrated different degrees of dissociation. These dissociated species could play a key role in the already complex pathophysiology of AL amyloidosis. The degree of dissociation is inversely proportional to the amyloid yield. Our results highlight the importance and physiological consequences of intermediates/fibril dissociation in AL amyloidosis.

Citing Articles

A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots.

Liu X, Wang J, Li Y, Shi W, Zhang X, Li S Front Med (Lausanne). 2024; 11:1441032.

PMID: 39139790 PMC: 11320149. DOI: 10.3389/fmed.2024.1441032.

Biophysical characterization of human-cell-expressed, full-length κI O18/O8, AL-09, λ6a, and Wil immunoglobulin light chains.

Misra P, Tischer A, Lampe L, Pierluissi-Ruiz V, Dick C, Bragantini B Biochim Biophys Acta Proteins Proteom. 2024; 1872(3):140993.

PMID: 38169170 PMC: 10939777. DOI: 10.1016/j.bbapap.2023.140993.

Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains.

Wong S, West M, Morgan G Protein Sci. 2023; 33(3):e4871.

PMID: 38100259 PMC: 10868443. DOI: 10.1002/pro.4871.

Role of the mechanisms for antibody repertoire diversification in monoclonal light chain deposition disorders: when a friend becomes foe.

Del Pozo-Yauner L, Herrera G, Perez Carreon J, Turbat-Herrera E, Rodriguez-Alvarez F, Ruiz Zamora R Front Immunol. 2023; 14:1203425.

PMID: 37520549 PMC: 10374031. DOI: 10.3389/fimmu.2023.1203425.

Mechanistic insights into the aggregation pathway of the patient-derived immunoglobulin light chain variable domain protein FOR005.

Pradhan T, Sarkar R, Meighen-Berger K, Feige M, Zacharias M, Reif B Nat Commun. 2023; 14(1):3755.

PMID: 37353525 PMC: 10290123. DOI: 10.1038/s41467-023-39280-0.

References

Buxbaum J . Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am. 1992; 6(2):323-46. View

Misra P, Blancas-Mejia L, Ramirez-Alvarado M . Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains. Biochemistry. 2019; 58(29):3155-3168. PMC: 6650354. DOI: 10.1021/acs.biochem.9b00311. View

Blancas-Mejia L, Ramirez-Alvarado M . Systemic amyloidoses. Annu Rev Biochem. 2013; 82:745-74. PMC: 4044913. DOI: 10.1146/annurev-biochem-072611-130030. View

Blancas-Mejia L, Misra P, Dick C, Marin-Argany M, Redhage K, Cooper S . Assays for Light Chain Amyloidosis Formation and Cytotoxicity. Methods Mol Biol. 2018; 1873:123-153. PMC: 6581042. DOI: 10.1007/978-1-4939-8820-4_8. View

Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H . A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015; 126(5):612-5. DOI: 10.1182/blood-2015-01-620302. View

Torrent J, Alvarez-Martinez M, Heitz F, Liautard J, Balny C, Lange R . Alternative prion structural changes revealed by high pressure. Biochemistry. 2003; 42(5):1318-25. DOI: 10.1021/bi0269916. View

ONuallain B, Thakur A, Williams A, Bhattacharyya A, Chen S, Thiagarajan G . Kinetics and thermodynamics of amyloid assembly using a high-performance liquid chromatography-based sedimentation assay. Methods Enzymol. 2006; 413:34-74. DOI: 10.1016/S0076-6879(06)13003-7. View

Smith D, Radford S, Ashcroft A . Elongated oligomers in beta2-microglobulin amyloid assembly revealed by ion mobility spectrometry-mass spectrometry. Proc Natl Acad Sci U S A. 2010; 107(15):6794-8. PMC: 2872402. DOI: 10.1073/pnas.0913046107. View

Takahashi Y, Okamoto Y, Popiel H, Fujikake N, Toda T, Kinjo M . Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. J Biol Chem. 2007; 282(33):24039-48. DOI: 10.1074/jbc.M704789200. View

10.

Foguel D, Suarez M, Ferrao-Gonzales A, Porto T, Palmieri L, Einsiedler C . Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A. 2003; 100(17):9831-6. PMC: 187855. DOI: 10.1073/pnas.1734009100. View

11.

Knowles T, Vendruscolo M, Dobson C . The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol. 2014; 15(6):384-96. DOI: 10.1038/nrm3810. View

12.

Marin-Argany M, Guell-Bosch J, Blancas-Mejia L, Villegas S, Ramirez-Alvarado M . Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils. Protein Sci. 2015; 24(11):1829-40. PMC: 4622216. DOI: 10.1002/pro.2790. View

13.

McWilliams-Koeppen H, Foster J, Hackenbrack N, Ramirez-Alvarado M, Donohoe D, Williams A . Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes. PLoS One. 2015; 10(9):e0137716. PMC: 4579077. DOI: 10.1371/journal.pone.0137716. View

14.

Blancas-Mejia L, Tischer A, Thompson J, Tai J, Wang L, Auton M . Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations. J Mol Biol. 2013; 426(2):347-61. PMC: 3892967. DOI: 10.1016/j.jmb.2013.10.016. View

15.

Randles E, Thompson J, Martin D, Ramirez-Alvarado M . Structural alterations within native amyloidogenic immunoglobulin light chains. J Mol Biol. 2009; 389(1):199-210. PMC: 2840394. DOI: 10.1016/j.jmb.2009.04.010. View

16.

Chen S, Drakulic S, Deas E, Ouberai M, Aprile F, Arranz R . Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc Natl Acad Sci U S A. 2015; 112(16):E1994-2003. PMC: 4413268. DOI: 10.1073/pnas.1421204112. View

17.

Kim Y, Wall J, Meyer J, Murphy C, Randolph T, Manning M . Thermodynamic modulation of light chain amyloid fibril formation. J Biol Chem. 2000; 275(3):1570-4. DOI: 10.1074/jbc.275.3.1570. View

18.

Sikkink L, Ramirez-Alvarado M . Salts enhance both protein stability and amyloid formation of an immunoglobulin light chain. Biophys Chem. 2008; 135(1-3):25-31. PMC: 2441971. DOI: 10.1016/j.bpc.2008.02.019. View

19.

Peterson F, Baden E, Owen B, Volkman B, Ramirez-Alvarado M . A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface. Structure. 2010; 18(5):563-70. PMC: 2872106. DOI: 10.1016/j.str.2010.02.012. View

20.

Abraham R, Geyer S, Price-Troska T, Allmer C, Kyle R, Gertz M . Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003; 101(10):3801-8. DOI: 10.1182/blood-2002-09-2707. View